EUVIMEDEUVIMED entdecken
Crossref

Genetic variability profiling of the p53 signaling pathway in chronic lymphocytic leukemia. Individual and combined analysis of TP53, MDM2 and NQO1 gene variants

María Belén Fontecha, María Del Rosario Anadón, Verónica Mercado Guzmán, Carmen Stanganelli, Camila Galvano, Fernanda Tosin, Javier Bordone, Raimundo Bezares, Cecilia Rodríguez, Viviana Heller, Irma Slavutsky, Ariela Freya Fundia iD

Annals of Hematology · 2024

DOI: 10.1007/s00277-024-05794-w ↗

Kurz gefasst

Fachartikel in der Zeitschrift Annals of Hematology, 2024. Verfasst von María Belén Fontecha und 11 weiteren Autor:innen. Beteiligte Einrichtung: Laboratorio de Farmacogenómica, Instituto de Medicina Experimental, CONICET-Academia Nacional de Medicina, Buenos Aires, Argentina. mbfontecha@gmail.…. Hauptthemen laut MEDLINE: Leukemia, Lymphocytic, Chronic, B-Cell, NAD(P)H Dehydrogenase (Quinone), Proto-Oncogene Proteins c-mdm2, Tumor Suppressor Protein p53. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 51 Literaturangaben. Gefördert von: Consejo Nacional de Investigaciones Científicas y Técnicas.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

TP53 gene disruption, including 17p13 deletion [del(17p)] and/or TP53 mutations, is a negative prognostic biomarker in chronic lymphocytic leukemia (CLL) associated with disease progression, treatment failure and shorter survival. Germline variants in p53 signaling pathway genes could also lead to p53 dysfunction, but their involvement in CLL has not been thoroughly evaluated. The aim of this study was to determine the association of TP53, MDM2 and NQO1 gene variability with clinical and genetic data of CLL patients. Individual genotype and haplotype data of CLL patients were compared with clinical prognostic factors, cytogenetic and molecular cytogenetic findings as well as IGHV and TP53 mutational status. The study included 116 CLL patients and 161 healthy blood donors. TP53 (rs1042522, rs59758982, rs1625895), NQO1 (rs1800566) and MDM2 (rs2279744, rs150550023) variants were genotyped using different PCR approaches. Analysis of genotype frequencies revealed no association with the risk of CLL. TP53 rs1042522, rs1625895 and MDM2 rs2279744 variants were significantly associated with abnormal karyotype and the presence of del(17p). Similarly, these two TP53 variants were associated with TP53 disruption. Moreover, TP53 C-A-nondel and G-A-del haplotypes (rs1042522-rs1625895-rs59758982) were associated with an increased likelihood of carrying del(17p) and TP53 disruptions. MDM2 T-nondel haplotype (rs2279744-rs150550023) was found to be a low risk factor for del(17p) (OR = 0.32; CI: 0.12-0.82; p = 0.02) and TP53 disruptions (OR = 0.41; CI: 0.18-0.95; p = 0.04). Our findings suggest that TP53 and MDM2 variants may modulate the risk to have chromosome alterations and TP53 disruptions, particularly del(17p). To our knowledge this is the first study of several germline variants in p53 pathway genes in Argentine patients with CLL.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Leukemia, Lymphocytic, Chronic, B-CellNAD(P)H Dehydrogenase (Quinone)Proto-Oncogene Proteins c-mdm2Tumor Suppressor Protein p53Signal TransductionHumansFemaleMaleMiddle AgedAgedAdultAged, 80 and overGenetic VariationPolymorphism, Single NucleotideHaplotypes

Stichwörter der Autor:innen

MDM2NQO1TP53Chronic lymphocytic leukemiaGermline variantsPolymorphisms

Substanzen

NAD(P)H Dehydrogenase (Quinone)Proto-Oncogene Proteins c-mdm2Tumor Suppressor Protein p53NQO1 protein, humanMDM2 protein, humanTP53 protein, human

Autor:innen und Institutionen

  • Laboratorio de Farmacogenómica, Instituto de Medicina Experimental, CONICET-Academia Nacional de Medicina, Buenos Aires, Argentina. mbfontecha@gmail.com.
  • Laboratorio de Farmacogenómica, Instituto de Medicina Experimental, CONICET-Academia Nacional de Medicina, Buenos Aires, Argentina.
  • Laboratorio de Biología Molecular, Hospital Alemán, Buenos Aires, Argentina.
  • División Patología Molecular, Instituto de Investigaciones Hematológicas, Academia Nacional de Medicina, Buenos Aires, Argentina.
  • Laboratorio de Genética de Neoplasias Linfoides, Instituto de Medicina Experimental, CONICET-Academia Nacional de Medicina, Buenos Aires, Argentina.
  • Servicio de Hematología, Hospital El Cruce, Buenos Aires, Argentina.

ORCID-Profile: Ariela Freya Fundia

Förderung

  • Consejo Nacional de Investigaciones Científicas y Técnicas

Zitieren

APA

Fontecha, M. B., Anadón, M. D. R., Mercado Guzmán, V., Stanganelli, C., Galvano, C., Tosin, F., Bordone, J., Bezares, R., Rodríguez, C., Heller, V., Slavutsky, I., & Fundia, A. F. (2024). Genetic variability profiling of the p53 signaling pathway in chronic lymphocytic leukemia. Individual and combined analysis of TP53, MDM2 and NQO1 gene variants. Annals of Hematology. https://doi.org/10.1007/s00277-024-05794-w

Vancouver

Fontecha MB, Anadón MDR, Mercado Guzmán V, Stanganelli C, Galvano C, Tosin F, et al. Genetic variability profiling of the p53 signaling pathway in chronic lymphocytic leukemia. Individual and combined analysis of TP53, MDM2 and NQO1 gene variants. Annals of Hematology. 2024. doi:10.1007/s00277-024-05794-w

BibTeX
@article{Fontecha2024,
  author = {Fontecha, María Belén and Anadón, María Del Rosario and Mercado Guzmán, Verónica and Stanganelli, Carmen and Galvano, Camila and Tosin, Fernanda and Bordone, Javier and Bezares, Raimundo and Rodríguez, Cecilia and Heller, Viviana and Slavutsky, Irma and Fundia, Ariela Freya},
  title = {Genetic variability profiling of the p53 signaling pathway in chronic lymphocytic leukemia. Individual and combined analysis of TP53, MDM2 and NQO1 gene variants},
  journal = {Annals of Hematology},
  year = {2024},
  doi = {10.1007/s00277-024-05794-w}
}
Kostenlos starten →